Compare W W Grainger Inc (GWW) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
W W Grainger Inc vs Illumina, Inc. — how do they compare? W W Grainger Inc trades at $1,309.29 (market cap $61.32B), while Illumina, Inc. trades at $190.72 (market cap $29.12B). The key difference: W W Grainger Inc is far larger — about 2.1× Illumina, Inc.'s market cap, and W W Grainger Inc pays a 0.77% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| GWW | ILMN | |
|---|---|---|
Market Cap | $61.32B | $29.12B |
Sector | Technology | Health |
52-Week High | $1.40K | $205.10 |
52-Week Low | $918.18 | $91.00 |
Enterprise Value | $63.53B | $30.48B |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,299.53, showing modest daily gains of 0.16%. The stock demonstrates strong fundamental performance with Q2 2026 earnings beating estimates at $12.01 per share versus $11.30 expected, and revenue reaching $5 billion. Technical indicators show bearish momentum with the current price between support at $1,282 and resistance at $1,305. The company raised its full-year 2026 outlook following strong quarterly results driven by margin expansion and market share gains.
GWW presents a mixed investment case with strong profitability metrics (ROE 47.92%, net margin 9.92%) offset by premium valuation (P/E 33.19). Analyst consensus leans cautious with 65.79% hold ratings despite recent earnings beats. Key risks include valuation concerns and competitive pressures in industrial distribution. The $1,320 consensus price target suggests limited upside from current levels, requiring careful monitoring of margin sustainability.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About W W Grainger Inc
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
